References
- Schalm SW. Treatment of chronic viral hepatitis anno 1990. Scand J Gastroenterol 1990; 25: 111–118, suppl 178
- Strander HA. Clinical effects of interferon therapy with special emphasis on antitumor efficacy. Acta Oncol 1989; 28: 355–362
- Öberg K. Treatment of neuroendocrine gut and pancreatic tumors with interferons. Acta Chir Scand 1989; 56–62, suppl 549
- Öberg K, Norheim I, Aim G. Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FL) and human leukocyte interferon. Eur J Cancer Clin Oncol 1989; 25: 1475–1479
- Hanssen L E, Schrumpf E, Kolbenstvedt A N, Tausjø, Dolva Lø. Treatment of malignant metastatic midgut carcinoid tumours with recombinant human x2b interferon with or without prior hepatic artery embolization. Scand J Gastroenterol 1989; 24: 787–795
- Eriksson B, Öberg K, Aim G, et al. Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon. Lancet 1986; 2: 1307–1308
- Öberg K, Aim G, Magnusson A, et al. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b; development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst 1989; 81: 531–535
- Krown SE. Kaposi's sarcoma and the acquired immune deficiency syndrome. Treatment with recombinant interferon alpha-A and analysis of prognostic factors. Cancer 1986; 57: 1662–1665
- Bartelsman J FWM, Sars P RA, Tijtgat G NJ. Gastrointestinal complications in patients with acquired immune deficiency syndrome. Scand J Gastroenterol 1989; 24: 112–117, suppl 171